Deep Survival Analysis With Clinical Variables for COVID-19

IEEE J Transl Eng Health Med. 2023 Mar 14:11:223-231. doi: 10.1109/JTEHM.2023.3256966. eCollection 2023.

Abstract

Objective: Millions of people have been affected by coronavirus disease 2019 (COVID-19), which has caused millions of deaths around the world. Artificial intelligence (AI) plays an increasing role in all areas of patient care, including prognostics. This paper proposes a novel predictive model based on one dimensional convolutional neural networks (1D CNN) to use clinical variables in predicting the survival outcome of COVID-19 patients.

Methods and procedures: We have considered two scenarios for survival analysis, 1) uni-variate analysis using the Log-rank test and Kaplan-Meier estimator and 2) combining all clinical variables ([Formula: see text]=44) for predicting the short-term from long-term survival. We considered the random forest (RF) model as a baseline model, comparing to our proposed 1D CNN in predicting survival groups.

Results: Our experiments using the univariate analysis show that nine clinical variables are significantly associated with the survival outcome with corrected p < 0.05. Our approach of 1D CNN shows a significant improvement in performance metrics compared to the RF and the state-of-the-art techniques (i.e., 1D CNN) in predicting the survival group of patients with COVID-19.

Conclusion: Our model has been tested using clinical variables, where the performance is found promising. The 1D CNN model could be a useful tool for detecting the risk of mortality and developing treatment plans in a timely manner.

Clinical impact: The findings indicate that using both Heparin and Exnox for treatment is typically the most useful factor in predicting a patient's chances of survival from COVID-19. Moreover, our predictive model shows that the combination of AI and clinical data can be applied to point-of-care services through fast-learning healthcare systems.

Keywords: CNN; COVID-19; clinical variables.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Artificial Intelligence*
  • Benchmarking
  • COVID-19*
  • Heparin
  • Humans
  • Survival Analysis

Substances

  • Heparin

Grants and funding

This work was supported in part by the National Natural Science Foundation of China under Grant 82260360, in part by the Foreign Young Talent Program under Grant QN2021033002L, and in part by the Guangxi Science and Technology Base and Talent Project under Grant 2022AC18004 and Grant 2022AC21040.